Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 6/20 | 0.48 |
| ▸ | QPCT | Q16769 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252702 | 0.89 | DGAT1 (0.66) | DGAT1GSK3BQPCTKDRFLT1 | |
| SCHEMBL1253144 | 0.88 | DGAT1 (0.68) | DGAT1GSK3BQPCTKDR | |
| SCHEMBL1252745 | 0.88 | DGAT1 (0.57) | DGAT1GSK3BNPBWR1QPCTKDR | |
| SCHEMBL1252134 | 0.88 | DGAT1 (0.57) | DGAT1GSK3BNPBWR1QPCTKDR | |
| SCHEMBL1252127 | 0.85 | DGAT1 (0.69) | DGAT1QPCTKDR | |
| SCHEMBL1252220 | 0.84 | GSK3B (0.49) | DGAT1GSK3BNPBWR1QPCTKDR | |
| SCHEMBL1250480 | 0.84 | DGAT1 (0.62) | DGAT1NPBWR1QPCTKDR | |
| SCHEMBL1252911 | 0.83 | DGAT1 (0.63) | DGAT1QPCTKDRFLT1 | |
| SCHEMBL1251920 | 0.83 | DGAT1 (0.60) | DGAT1GSK3BQPCTKDR | |
| SCHEMBL1252753 | 0.82 | DGAT1 (0.62) | DGAT1QPCTKDRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GSK3B 4067/4885NPBWR1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.